Hormone receptor +ve advanced breast cancer in postmenopausal women. Adjuvant treatment of hormone receptor +ve early invasive breast cancer in postmenopausal women & those who have received 2-3 yr of adjuvant tamoxifen.
Not to be used in premenopausal women. Not to be used in boys & girls w/ growth hormone deficiency in addition to growth hormone treatment. May reduce bone mineral density w/ possible consequent increased risk of fracture. Assess bone mineral density in women w/ or at risk of osteoporosis at commencement of treatment & regularly thereafter. Concomitant use w/ LHRH analogues. Avoid co-administration w/ tamoxifen or estrogen-containing therapies. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Severe renal impairment (GFR <30 mL/min). Moderate to severe hepatic impairment. Not recommended in childn & adolescents.
Sign Out
